Fei Shao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fei Shao has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Chongkai Shen
Center for Rehabilitation Medicine, Department of Psychiatry, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China (Yu, Shao); The Second Clinical Medical College of Zhejiang, Chinese Medicine University, Hangzhou, Zhejiang, China (Zhang); Hangzhou Xiaoshan No 2 People’s Hospital, Hangzhou, Zhejiang, China (Shen)
3 shared publicationsSijie Yu
Center for Rehabilitation Medicine, Department of Psychiatry, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China (Yu, Shao); The Second Clinical Medical College of Zhejiang, Chinese Medicine University, Hangzhou, Zhejiang, China (Zhang); Hangzhou Xiaoshan No 2 People’s Hospital, Hangzhou, Zhejiang, China (Shen)
3 shared publicationsYuhan Zhang
Center for Rehabilitation Medicine, Department of Psychiatry, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China (Yu, Shao); The Second Clinical Medical College of Zhejiang, Chinese Medicine University, Hangzhou, Zhejiang, China (Zhang); Hangzhou Xiaoshan No 2 People’s Hospital, Hangzhou, Zhejiang, China (Shen)
2 shared publicationsYafeng Song
Xiaoshan District social welfare Institute
1 shared publication
Latest Publications
- 1 July 2024
- Published by American Psychiatric Association Publishing in FOCUS
- Vol. 22 (3) , 388-399
Efficacy of Pharmacotherapies for Bulimia Nervosa: A Systematic Review and Meta-Analysis
The main purpose was to evaluate the efficacy and tolerability of different medications used to treat bulimia nervosa (BN). Randomized controlled trials (RCTs) were identified from published sources through searches in PubMed, Cochrane Library, Web of Science, and Embase from inception to November 2022. Primary outcomes were changes in the frequency of binge eating episodes and vomiting episodes from baseline to endpoint. Secondary outcomes were differences in the improvement of scores in depressive symptoms, tolerability (dropout due to adverse events) and weight change. The literature search ultimately included 11 drugs, 33 studies and 6 types of drugs, 8 trials with TCAs (imipra-mine, desipramine), 14 with SSRIs (fluoxetine, citalopram and fluvoxamine), 6 with MAOIs (phenelzine, moclobemide and brofaromine), 3 with antiepileptic drugs (topiramate), 1 with mood stabilizers (lithium), and 1 with amphetamine-type appetite suppressant (fenfluramine). The reduction in binge eating episodes was more likely due to these drugs than the placebo, and the SMD was -0.4 (95% CI -0.61 ∼ -0.19); the changes in the frequency of vomiting episodes (SMD = -0.16, 95% CI -0.3 ∼ -0.03); weight (WMD = -3.05, 95% CI -5.97 ∼ -0.13); and depressive symptoms (SMD =-0.32, 95% CI -0.51 ∼ -0.13). However, no significant difference was found in dropout due to adverse events (RR = 1.66, 95% CI 1.14 ∼ 2.41). This meta-analysis indicates that most pharmacotherapies decreased the frequency of binge-eating and vomiting episodes, body weight, and depressive symptoms in BN patients, but the efficacy was not significant. In each drug the efficacy is different, treating different aspects, different symptoms to improve the clinical performance of bulimia nervosa.Appeared originally in BMC Pharmacol Toxicol 2023; 24:72.
- 1 July 2024
- Published by American Psychiatric Association Publishing in FOCUS
- Vol. 22 (3) , 388-399
Efficacy of Pharmacotherapies for Bulimia Nervosa: A Systematic Review and Meta-Analysis
The main purpose was to evaluate the efficacy and tolerability of different medications used to treat bulimia nervosa (BN). Randomized controlled trials (RCTs) were identified from published sources through searches in PubMed, Cochrane Library, Web of Science, and Embase from inception to November 2022. Primary outcomes were changes in the frequency of binge eating episodes and vomiting episodes from baseline to endpoint. Secondary outcomes were differences in the improvement of scores in depressive symptoms, tolerability (dropout due to adverse events) and weight change. The literature search ultimately included 11 drugs, 33 studies and 6 types of drugs, 8 trials with TCAs (imipra-mine, desipramine), 14 with SSRIs (fluoxetine, citalopram and fluvoxamine), 6 with MAOIs (phenelzine, moclobemide and brofaromine), 3 with antiepileptic drugs (topiramate), 1 with mood stabilizers (lithium), and 1 with amphetamine-type appetite suppressant (fenfluramine). The reduction in binge eating episodes was more likely due to these drugs than the placebo, and the SMD was -0.4 (95% CI -0.61 ∼ -0.19); the changes in the frequency of vomiting episodes (SMD = -0.16, 95% CI -0.3 ∼ -0.03); weight (WMD = -3.05, 95% CI -5.97 ∼ -0.13); and depressive symptoms (SMD =-0.32, 95% CI -0.51 ∼ -0.13). However, no significant difference was found in dropout due to adverse events (RR = 1.66, 95% CI 1.14 ∼ 2.41). This meta-analysis indicates that most pharmacotherapies decreased the frequency of binge-eating and vomiting episodes, body weight, and depressive symptoms in BN patients, but the efficacy was not significant. In each drug the efficacy is different, treating different aspects, different symptoms to improve the clinical performance of bulimia nervosa.Appeared originally in BMC Pharmacol Toxicol 2023; 24:72.
- Open Access
- 2 December 2023
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 24 (1) , 1-16
Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis
Objective: The main purpose was to evaluate the efficacy and tolerability of different medications used to treat bulimia nervosa (BN). Methods: Randomized controlled trials (RCTs) were identified from published sources through searches in PubMed, Cochrane Library, Web of Science, and Embase from inception to November 2022. Primary outcomes were changes in the frequency of binge eating episodes and vomiting episodes from baseline to endpoint. Secondary outcomes were differences in the improvement of scores in depressive symptoms, tolerability (dropout due to adverse events) and weight change. Results: The literature search ultimately included 11 drugs, 33 studies and 6 types of drugs, 8 trials with TCAs (imipramine, desipramine), 14 with SSRIs (fluoxetine, citalopram and fluvoxamine), 6 with MAOIs (phenelzine, moclobemide and brofaromine), 3 with antiepileptic drugs (topiramate), 1 with mood stabilizers (lithium), and 1 with amphetamine-type appetite suppressant (fenfluramine). The reduction in binge eating episodes was more likely due to these drugs than the placebo, and the SMD was -0.4 (95% CI -0.61 ~ -0.19); the changes in the frequency of vomiting episodes (SMD = -0.16, 95% CI -0.3 ~ -0.03); weight (WMD = -3.05, 95% CI -5.97 ~ -0.13); and depressive symptoms (SMD = -0.32, 95% CI -0.51 ~ -0.13). However, no significant difference was found in dropout due to adverse events (RR = 1.66, 95% CI 1.14 ~ 2.41). Conclusions: This meta-analysis indicates that most pharmacotherapies decreased the frequency of binge-eating and vomiting episodes, body weight, and depressive symptoms in BN patients, but the efficacy was not significant. In each drug the efficacy is different, treating different aspects, different symptoms to improve the clinical performance of bulimia nervosa.
- 2 December 2023
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 24 (1) , 1-16
Open AccessEfficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis
Objective: The main purpose was to evaluate the efficacy and tolerability of different medications used to treat bulimia nervosa (BN). Methods: Randomized controlled trials (RCTs) were identified from published sources through searches in PubMed, Cochrane Library, Web of Science, and Embase from inception to November 2022. Primary outcomes were changes in the frequency of binge eating episodes and vomiting episodes from baseline to endpoint. Secondary outcomes were differences in the improvement of scores in depressive symptoms, tolerability (dropout due to adverse events) and weight change. Results: The literature search ultimately included 11 drugs, 33 studies and 6 types of drugs, 8 trials with TCAs (imipramine, desipramine), 14 with SSRIs (fluoxetine, citalopram and fluvoxamine), 6 with MAOIs (phenelzine, moclobemide and brofaromine), 3 with antiepileptic drugs (topiramate), 1 with mood stabilizers (lithium), and 1 with amphetamine-type appetite suppressant (fenfluramine). The reduction in binge eating episodes was more likely due to these drugs than the placebo, and the SMD was -0.4 (95% CI -0.61 ~ -0.19); the changes in the frequency of vomiting episodes (SMD = -0.16, 95% CI -0.3 ~ -0.03); weight (WMD = -3.05, 95% CI -5.97 ~ -0.13); and depressive symptoms (SMD = -0.32, 95% CI -0.51 ~ -0.13). However, no significant difference was found in dropout due to adverse events (RR = 1.66, 95% CI 1.14 ~ 2.41). Conclusions: This meta-analysis indicates that most pharmacotherapies decreased the frequency of binge-eating and vomiting episodes, body weight, and depressive symptoms in BN patients, but the efficacy was not significant. In each drug the efficacy is different, treating different aspects, different symptoms to improve the clinical performance of bulimia nervosa.
- Open Access
- 8 September 2023
- Published by Springer Nature in Research Square
Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis
Objective The main purpose was to evaluate the efficacy and tolerability of different medications used to treat bulimia nervosa(BN). Methods Randomized controlled trials (RCTs) were identified from published sources through searches in PubMed, Cochrane Library, Web of Science, and Embase, from inception to November 2022. Primary outcomes were: changes in the frequency of binge eating episodes and vomiting episodes from baseline to endpoint. Secondary outcomes were difference in the improvement of scores in depressive symptoms; tolerability (dropout due to adverse events) and weight change. Results The literature search ultimately included 11 drugs, 33 studies and 6 types of medicine, 8 trials with TCAs (imipramine, desipramine and amitriptyline), 14 with SSRIs (fluoxetine, citalopram and fluvoxamine), 6 with MAOIs (phenelzine, moclobemide and brofaromine), 3 with antiepileptic drugs (topiramate), 1 with mood stabilizer (lithium), 1 with amphetamine-type appetite suppressant (fenfluramine). In the reduction of binge eating episodes was more likely on these drugs than placebo, the SMD was − 0.4 (95% CI -0.61~-0.19); about the changes in the frequency of vomiting episodes (SMD=-0.16, 95% CI -0.3~-0.03); weight (WMD=-3.05, 95% CI -5.97~-0.13); depressive symptoms (SMD=-0.29 ,95% CI -0.48~-0.11). However, no statistical difference was found in dropout due to adverse events (RR = 1.62, 95% CI 0.98 ~ 2.67). Conclusions This meta-analysis indicates that most pharmacotherapies declined the frequency of binge-eating and vomiting episode, body weight, and depressive symptoms in BN patients, but the efficacy is not very significant. In each medicine, the efficacy is not the same, which through different aspects, different symptoms to improve the clinical performance of bulimia nervosa.
- 8 September 2023
- Published by Springer Nature in Research Square
Open AccessEfficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis
Objective The main purpose was to evaluate the efficacy and tolerability of different medications used to treat bulimia nervosa(BN). Methods Randomized controlled trials (RCTs) were identified from published sources through searches in PubMed, Cochrane Library, Web of Science, and Embase, from inception to November 2022. Primary outcomes were: changes in the frequency of binge eating episodes and vomiting episodes from baseline to endpoint. Secondary outcomes were difference in the improvement of scores in depressive symptoms; tolerability (dropout due to adverse events) and weight change. Results The literature search ultimately included 11 drugs, 33 studies and 6 types of medicine, 8 trials with TCAs (imipramine, desipramine and amitriptyline), 14 with SSRIs (fluoxetine, citalopram and fluvoxamine), 6 with MAOIs (phenelzine, moclobemide and brofaromine), 3 with antiepileptic drugs (topiramate), 1 with mood stabilizer (lithium), 1 with amphetamine-type appetite suppressant (fenfluramine). In the reduction of binge eating episodes was more likely on these drugs than placebo, the SMD was − 0.4 (95% CI -0.61~-0.19); about the changes in the frequency of vomiting episodes (SMD=-0.16, 95% CI -0.3~-0.03); weight (WMD=-3.05, 95% CI -5.97~-0.13); depressive symptoms (SMD=-0.29 ,95% CI -0.48~-0.11). However, no statistical difference was found in dropout due to adverse events (RR = 1.62, 95% CI 0.98 ~ 2.67). Conclusions This meta-analysis indicates that most pharmacotherapies declined the frequency of binge-eating and vomiting episode, body weight, and depressive symptoms in BN patients, but the efficacy is not very significant. In each medicine, the efficacy is not the same, which through different aspects, different symptoms to improve the clinical performance of bulimia nervosa.